How big is Semler Scientific, Inc.?

As of Jun 18, Semler Scientific, Inc. has a market capitalization of 324.27 million, with net sales of 49.22 million and a net profit of -29.87 million over the last four quarters. Shareholder's funds are reported at 230.75 million, and total assets amount to 243.04 million.

As of Jun 18, Semler Scientific, Inc. has a market capitalization of 324.27 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 49.22 million, while the sum of net profit for the same period is -29.87 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 230.75 million, and total assets amount to 243.04 million.

What does Semler Scientific, Inc. do?

Semler Scientific, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $9 million and a net profit of -$65 million. It has a market cap of $324.27 million and key metrics include a P/E ratio of 24.00 and a return on equity of 9.82%.

Overview:<BR>Semler Scientific, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -65 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 324.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 24.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.06 <BR>Return on Equity: 9.82% <BR>Price to Book: 2.01<BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Semler Scientific, Inc.?

Is Semler Scientific, Inc. overvalued or undervalued?

As of August 4, 2025, Semler Scientific, Inc. has improved from a risky to an attractive valuation grade, appearing undervalued with a P/E ratio of 24, despite a year-to-date stock performance of -45.39% compared to the S&P 500's 12.22%.

As of 4 August 2025, the valuation grade for Semler Scientific, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. Based on the current metrics, the company appears to be undervalued, with a P/E ratio of 24, an EV to EBITDA of 27.71, and a Price to Book Value of 2.32. In comparison, its peer Axogen, Inc. has a P/E ratio of -146.35, while Bioventus, Inc. shows a P/E of 72.81, highlighting the relative attractiveness of Semler's valuation.<BR><BR>Despite recent challenges reflected in its stock performance, where it has underperformed the S&P 500 over various periods, including a YTD return of -45.39% compared to the S&P 500's 12.22%, the overall valuation metrics suggest that Semler Scientific, Inc. is positioned favorably within its industry.

Is Semler Scientific, Inc. technically bullish or bearish?

As of August 19, 2025, Semler Scientific, Inc. is in a bearish trend, indicated by negative signals from MACD, RSI, and moving averages, with a year-to-date return of -45.39% compared to the S&P 500's 12.22%.

As of 19 August 2025, the technical trend for Semler Scientific, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, the monthly RSI is bearish, and daily moving averages also reflect a bearish trend. Additionally, Bollinger Bands and KST are bearish on a monthly basis, while Dow Theory and OBV show a mildly bearish stance on the weekly timeframe. <BR><BR>In terms of performance, the stock has underperformed significantly against the S&P 500, with a year-to-date return of -45.39% compared to the S&P 500's 12.22%, and a 3-year return of -26.55% versus the S&P 500's 70.41%.